Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
Presentations highlight research involving Enveric’s EVM301 Series of non-hallucinogenic neuroplastogens and the company’s lead product candidate, EB-373 ...